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Clostridioides difficile is the causative bacterium in 15–20% of all antibiotic associated
diarrheas. The symptoms associated with C. difficile infection (CDI) are primarily
induced by the two large exotoxins TcdA and TcdB. Both toxins enter target cells by
receptor-mediated endocytosis. Although different toxin receptors have been identified,
it is no valid therapeutic option to prevent receptor endocytosis. Therapeutics, such as
neutralizing antibodies, directly targeting both toxins are in development. Interestingly,
only the anti-TcdB antibody bezlotoxumab but not the anti-TcdA antibody actoxumab
prevented recurrence of CDI in clinical trials. In this work, 31 human antibody fragments
against TcdB were selected by antibody phage display from the human naive antibody
gene libraries HAL9/10. These antibody fragments were further characterized by in vitro
neutralization assays. The epitopes of the neutralizing and non-neutralizing antibody
fragments were analyzed by domain mapping, TcdB fragment phage display, and peptide
arrays, to identify neutralizing and non-neutralizing epitopes. A new neutralizing epitope
within the glucosyltransferase domain of TcdB was identified, providing new insights into
the relevance of different toxin regions in respect of neutralization and toxicity.
Keywords: Toxin B (TcdB),Clostridioides difficile, antibody phage display, recombinant antibody, epitopemapping,
neutralization, scFv, scFv-Fc
INTRODUCTION
By the end of the 1970s, Clostridioides (former Clostridium) difficile (CDiff) was identified as the
causative pathogen of antibiotic treatment associated diarrhea (CDAD) (Bartlett et al., 1978). Since
then, the number of CDiff infections (CDI) has been increasing and in the last two decades CDiff
even caused epidemic outbreaks (Rupnik et al., 2009; DePestel and Aronoff, 2013). In 2011, CDiff
caused∼453,000 incident infections in the USA with∼29,000 deaths (Lessa et al., 2015). Due to its
association with antibiotic treatment and the resulting high potential for development of antibiotic
resistance, the Centers for Disease Control and Prevention (CDC) classify CDiff as an urgent threat
(Centers of Disease Control Prevention, 2013).
In standard therapy for mild to moderate CDI, CDiff is targeted with metronidazole,
vancomycin or fidaxomicin (Tedesco et al., 1978; Bolton and Culshaw, 1986; Goldstein et al.,
2012). However, antibiotic therapy presumably further disrupts the gut microbiome that confers
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colonization resistance against CDiff. Hence, in 20–30% of CDI
cases, recurrences or relapses occur within 2–6 weeks after
completion of antibiotic treatment (Pépin et al., 2006). Another
concern about antibiotic therapy is the high potential of CDiff
to evolve resistances (Centers of Disease Control Prevention,
2013; Gao and Huang, 2015), therefore, alternative therapeutic
approaches are urgently needed.
Disease and typical symptoms of CDI are only caused by
strains that express at least Toxin B (TcdB), mostly together with
Toxin A (TcdA) (Natarajan et al., 2013). Some strains also express
an additional binary Toxin CDT, but its role in disease is still
poorly understood (Gerding et al., 2014).
In the last two decades, the incidence of so-called
hypervirulent CDiff strains has increased. These strains
carry mutations within the toxin repressor gene tcdc, which may
lead to higher toxin expression levels and, therefore, to more
severe disease (Razavi et al., 2007; Joost et al., 2009).
TcdA and TcdB are homologous single-chain multidomain
proteins with a molecular weight of 308 and 270 kDa,
respectively. A schematic representation of TcdB is given in
Figure 1.
The N-terminal glucosyltransferase domain (GTD, TcdB aa 1–
543) acts on small Rho-GTPases, e.g., RhoA, within the cytosol of
the host’s cells (Just et al., 1995; Busch et al., 1998). Due to the
monoglucosylation, the GTPases are trapped in an inactive state,
which inhibits multiple signal cascades, leading to cytoskeleton
breakdown and consequently cell rounding (Rothman et al.,
1984; Erdmann et al., 2017).
Amino acids 544–767 build up a cysteine protease domain
(CPD) that catalyzes the proteolytic auto-processing and releases
the GTD into the cytosol upon translocation, after activation
induced by cytosolic inositol-6 phosphate (InsP6) (Egerer et al.,
2007; Reineke et al., 2007; Shen et al., 2011).
Amino acids 768–1852 form the translocation domain
(TLD). Despite notable progress during the last years, the
exact function and the molecular mechanisms involving this
huge domain are still elusive. The TLD includes a stretch
of amino acids (aa 830–990), which are proposed to be
involved in pore formation for translocation of the N-terminal
portion across the endosome membrane upon acidification
(Genisyuerek et al., 2011). Furthermore, for TcdB three
putative receptors binding regions have been identified recently
within this domain, which interact with the following cell
surface receptors: chondroitin sulfate proteoglycan 4 (CSPG4),
polio virus receptor like 3 (PVRL3) or members of the
frizzled protein family (FZD1/2/7) (LaFrance et al., 2015;
Yuan et al., 2015; Tao et al., 2016; Gupta et al., 2017).
The role of these receptor binding sites in disease is still
unknown.
The C-terminus of both toxins is composed of repetitive
elements, where long and short repeats are combined in so-
called CROPs (combined repetitive oligo peptides) (von Eichel-
Streiber et al., 1992). In case of TcdA, the CROPs interact with
carbohydrate structures [α-Gal-(1,3)-β-Gal-(1,4)-β-GlcNAc] on
the cell surface of the target cells, mediating a first contact
between toxin and target cell (Krivan et al., 1986; Greco et al.,
2006) and prevent premature autoproteolytic cleavage of the
toxin, by stabilization of the toxin conformation (Olling et al.,
2014). For TcdB the role of the CROPs is less defined, but due to
the homology similar functions can be assumed. Recently it had
been shown, that next to residues within the TLD the first three
short repeats of the CROPs are also involved in CSPG4 binding
(Gupta et al., 2017).
Since TcdA and TcdB are the major virulence factors of CDiff
responsible for damage of the gut epithelium upon CDI, efforts
have been made to develop therapeutics that directly target the
toxins instead of the bacterium (Kurtz et al., 2001; Puri et al.,
2015; Sturino et al., 2015; Ivarsson et al., 2017). One of these is the
human monoclonal anti-TcdB antibody Bezlotoxumab, recently
approved by the FDA as therapeutic for prevention of recurrent
CDI (U.S. Food and Drug Administration, 2016). However, this
antibody only reduces the relapse rate by ∼40% (Navalkele and
Chopra, 2018) and is not approved for treatment of acute CDI.
Crystal structure analysis revealed binding of Bezlotoxumab to
two homologous epitopes within the CROPs domain (Orth et al.,
2014). For either TcdA and TcdB it had been shown that toxicity
is partially reduced, but not abolished in CROPs deletionmutants
(Frisch et al., 2003; Olling et al., 2011; Manse and Baldwin,
2015), pointing out functionally independent receptor binding
sites within at least TcdB, which could also affect neutralization
efficacy of Bezlotoxumab. Therefore, a combined approach
with a mixture of antibodies that target different epitopes or
domains may further improve toxin neutralization and clinical
outcome.
In this study, we describe the generation of a panel of human
antibodies targeting different domains of TcdB by a phage display
approach using the naïve human antibody libraries HAL9 and
HAL10 (Kügler et al., 2015). In a cell based assay, the generated
antibodies were screened for TcdB neutralization. Furthermore,
domain and epitope mapping of the neutralizing and non-
neutralizing antibodies was performed by antigen ELISA, peptide
array (Weber et al., 2017a,b) and phage display.Wemapped TcdB
in respect to its epitopes, related to neutralization or, respectively,
to non-neutralization. These resultsgive new insights into the
relevance of different toxin regions regarding neutralization and
toxicity. In addition, we identified a new epitope within the N-
terminal glucosyltransferase domain (GTD) of TcdB that conveys
neutralization.
METHODS
Antigen Production
Full length TcdB from Clostridioides difficile strain VPI10463
(identical to TcdB from strain cdi630) as well as toxin
fragments and isolated domains were recombinantly expressed
as C-terminally 6 × His-tagged proteins in the Bacillus
megaterium expression system (MoBiTec, Germany) (Burger
et al., 2003), except for TcdBCROP domain (aa 1853–2366) which
was expressed as GST-fusion protein in E. coli. Full length
TcdB1−2366 (TcdBFL), TcdB1−1852, TcdB1−1128, and TcdB1−542
(TcdBGTD) were cloned into pHIS1522 via BsrGI and BamHI
(Wohlan et al., 2014). For production of TcdBGTD we used the
glucosyltransferase-deficient mutant TcdB1−542 D286/288N for
higher yield and purity of protein. The His-tagged proteins were
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FIGURE 1 | Schematic representation of TcdB fragments used in this study. All fragments were derived from TcdB of C. difficile strain VPI10463. TcdBFL: wild type
(wt) TcdB, TcdB1−1852: wt TcdB missing the CROP domain, TcdB1−1128: N-terminal 1128 aa of wt TcdB, TcdBGTD: enzymatically inactive mutant (D286/288N) of
TcdB glucosyltransferase domain, TcdBCROPs combined repetitive oligopeptides, missing the first short repeat.
purified via Ni2+-affinity chromatography (Ni-IDA columns,
Machery-Nagel, Germany) by gravity flow after protocol supplied
by company. The purified proteins were stored at −80◦C
in storage buffer (50mM NaCl, 20mM Tris HCl, pH 8.0)
after buffer exchange via Zeba desalting columns (Pierce,
Thermofisher). The TcdBCROP domain was expressed as N-
terminal GST fusion protein. The fusion protein was purified
via glutathione (GSH)-sepharose (GE Healthcare) after standard
protocol in E. coli lysis buffer (20mM Tris, pH 8.0, 50mM NaCl,
1mM dithiothreitol). TcdBCROP was cleaved directly from GSH-
sepharose bound GST-tag by thrombin at 4◦C overnight. The
purity and specific concentration of all proteins was estimated by
SDS-PAGE.
Antibody Generation
Antibodies against TcdB were selected in scFv-format from the
human naïve antibody gene libraries HAL9 and HAL10 (Kügler
et al., 2015). The selection and screening was performed as
described before (Russo et al., 2018a). In brief, for antibody
selection, scFv phage from HAL9 and HAL10 were mixed and
incubated on TcdBFL, TcdB1−1852, or TcdBCROPs, immobilized in
Costar High Binding microtiter plates (Sigma-Aldrich Chemie
GmbH, Munich, Germany). Panning was performed at 37◦C
or room temperature. In two approaches, negative selection of
the library on immobilized TcdB1−1128 was used to specifically
isolate binders directed against the TLD domain of TcdB. After
three rounds of panning, monoclonal soluble scFv were produced
and screened for TcdB binding by antigen-ELISA. DNA of
binding candidates was isolated and sequenced. The unique
scFv sequences were recloned into pCSE2.6-hIgG1-Fc-XP (Beer
et al., 2018; Russo et al., 2018b) using NcoI/NotI (NEB) for
mammalian production as scFv-Fc, an IgG-like antibody format.
The production in HEK293-6E cells and subsequent protein
A purification was performed as described before (Jäger et al.,
2013)
Domain Mapping by Antigen ELISA
Costar High Binding microtiter plate were coated with 100 ng
of TcdB fragments or full length TcdB (TcdBFL) in 100 µL of
PBS overnight at 4◦C. After saturating the wells with 250 µL
MPBST (PBS with 0.05% (v/v) Tween20 and 2% (w/v) milk
powder) and three times washing, a serial dilution of scFv-
Fc in MPBST was added to the plate and incubated for 1 h
at room temperature followed by three times washing. Bound
scFv-Fcs were detected using a Fcγ specific HRP conjugated
antibody (Sigma Aldrich, A0170, 1:70,000 in MPBST) for 45min
incubation at room temperature followed by 3x washing. The
detection was performed using TMB substrate. The colorimetric
reaction was stopped by addition of 100 µL 0.5M H2SO4
and measured with an ELISA reader (TECAN Sunrise, 450 nm,
reference 620 nm).
SDS-PAGE and Immunoblot
TcdB was heated to 96◦C in Leammli buffer with 3% 2–
Mercaptoethanol for 10min to denature. Five microgram of
denatured TcdB was applied to an 10% SDS-PAGE and separated
at 200V for 45min. The protein was transferred to a PVDF
membrane using the Trans-Blot R© TurboTM (BioRad) transfer
system according to manufacturer’s instructions using the high
molecular weight program (1.3A, 25V, 10min). The membrane
was blocked inMPBST and placed into aMini-Protean R©II multi-
screen chamber (BioRad). The channels were completely filled
with scFv-Fcs diluted in MPBST to a concentration of 1µg/mL.
After 1.5 h the channels were washed three times with PBST. The
membrane was removed from the multi-screen chamber washed
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again with PBST and incubated with an anti-human IgG (Fcγ
specific) AP conjugated antibody (Jackson Immuno Research
Laboratories 109-055-098) in a 1:20,000 dilution inMPBST. After
1 h the membrane was washed 2 times with PBST and once
with AP substrate buffer (100mM Tris HCl pH 9.5, 0.5mM
MgCl2. Afterwards the immunoblot was developed with nitro
blue tetrazolium chloride (0.30 mg/mL) and 5-Bromo-4-chloro-
3-indolyl phosphate (0.15 mg/mL) in AP substrate buffer. The
color reaction was stopped by removing the substrate through
washing with water. The membrane was dried between paper
towels and scanned.
Cultivation of Vero Cells and in vitro TcdB
Neutralization Assay
For in vitro TcdB neutralization assay a Vero cell line (African
green monkey kidney cells) was used. TcdB treatment leads to a
breakdown of the actin cytoskeleton which leads to cell rounding.
This effect is easily visible using bright field microscopy.
Vero cells were cultivated in RPMI medium supplemented
with 2.0 g/L NaHCO3, 2mM stable glutamine (FG1215,
Biochrom) and 10% fetal calf serum at 37◦C and 5% (v/v) CO2
and passaged 2–3 times per week when confluency exceeded
90%. In an initial assay the working concentration of TcdB was
determined. Therefore, Vero cells were seeded at a density of
10,000 cells per well in a 96 well cell culture plate (Cellstar R©,
Greiner bio-one) 16 h before intoxication, TcdBFL was diluted in
cultivation media and a serial dilution was prepared. Consumed
media was removed from the cells, and TcdBFL dilutions were
added. Cells were incubated at 37◦C and 5% CO2 for 5 h. Pictures
of the wells were collected (Zeiss Axiovert 200 with Hamamatsu
C4742-95 digital camera) and the percentage of round cells was
determined by software assisted counting (Image J).
For neutralization assay, cells were prepared as described
above and 0.1 pM TcdBFL was premixed with scFv-Fc
in cultivation media. After incubation of 30min at room
temperature the antibody TcdBFL mixture was transferred to the
cells. Pictures of the wells were collected when the percentage of
round cells in the control wells (TcdBFL w/o antibody) reached
70–80%.
Construction and Packaging of
TcdB-Fragment Phage Display Library
The pHORF-tcdB-fragment library was generated as described
before (Zantow et al., 2016) with minor adjustments. In brief,
tcdB was amplified from genomic DNA of Clostridioides difficile
strain 630 (kindly provided by Meina Neumann-Schaal, DSMZ)
by PCR using Phusion DNA polymerase and the following
oligonucleotides as primers:
5′ATGAGTTTAGTTAATAGAAAACAGTTAGAAAAAATGG
3′ (forward),
5′CTATTCACTAATCACTAATTGAGCTGTATCAGG
3′ (reverse)
PCR product was fragmented using Bioruptor R© Pico sonicator
(Diagenode) using following settings: 4◦C, 45 cycles, 30 s
sonication (low intensity), 30 s pause. Fragmented DNA was
concentrated using Amicon Ultra Centrifugal filters (30K
MWCO, Millipore). Cohesive ends were blunted and blunt ends
were phosphorylated according to manufacturer’s instructions
(Fast DNA End Repair Kit, Thermo Scientific). DNA product
was purified using HiYield R© Gel/PCR DNA fragment extraction
kit, (SLG). A 10-fold molar excess of gene fragments was ligated
into PmeI (NEB) linearized andCIP (Calf Instestine Phosphatase,
NEB) dephosphorylated pHORF3 library vector (Kügler et al.,
2008) (16 h at 16◦C, T4 DNA Ligase, Promega). The ligase was
inactivated at 65◦C for 10min and the buffer was exchanged
to H2O using Amicon Ultra Centrifugal Filters (30K MWCO).
Five microliter of ligation was used to transform 25 µL of
electrocompetent E. coli TOP10F’ (TOP10F’ ElectrocompTM Kit,
Life Technologies) by electroporation (1.8 kV, MicroPulserTM,
BioRad). Successfully transformed TOP10F’ cells were selected
on 2 × YT agar [1.6% (w/v) tryptone, 1% (w/v) yeast extract,
0.05% (w/v) NaCl, 1.2% (w/v) agar] supplemented with 100mM
glucose and 100µg/mL ampicillin.
Determination of transformation rate and packaging of
oligopeptide phage library and ORF enrichment was performed
as described before (Zantow et al., 2016). Gene coverage andORF
enrichment was analyzed by sequencing of individual E. coli XL1
blue MRF’ clones infected with TcdB-gene fragment phage.
Epitope Mapping by Phage Display
Epitope mapping by phage display was either conducted
by panning on scFv-Fc immobilized in Costar High
Binding microtiter plates or as a panning in solution with
immunoprecipitation using Protein A coupled magnetic beads
(SureBeads, BioRad) with subsequent screening ELISA using
monoclonal TcdB-fragment phage.
Panning on Immobilized scFv-Fc
For negative-selection of the TcdB-fragment phage display
library, an irrelevant scFv-Fc (1 µg in 100 µL PBS/well) was
immobilized in a Costar High Binding microtiter plate. After
blocking with 250 µL panningblock [PBS with 0.05% (v/v)
Tween20, 1% w/v BSA and 1% w/v milk powder] and 3x washing
of the cavity using Tecan Columbus microplate washer, 109
cfu TcdB-fragment-phage diluted in 150 µL panningblock were
incubated in the negative-selection well for 1 h. The supernatant
of the negative selection well and 1 µg of the irrelevant scFv-Fc
for competition were transferred to the first of three successive
panning wells, which had been coated overnight at 4◦C with 1 µg
of the scFv-Fc of interest and blocked with MPBST (PBS with
0.05% (v/v) Tween20, and 2% w/v milk powder). After 1 h of
incubation, the phage were transferred to the second panning
well, after one further hour to the third well. To prevent the first
and the second well from drying, 1 µg of the irrelevant scFv-Fc
diluted in 150 µL PBST was added immediately after transfer.
To remove unbound phage, the first well was washed 10x with a
harsh bottom wash program using Tecan Columbus microplate
washer, the second well was washed 6x and the third well 3x using
PBST. Remaining phage were eluted with 150 µL trypsin in PBS
(10 µg /mL) by incubation at 37◦C for 30min. 10 µL of eluted
phage were used to infect 50 µL E. coli XL1 blue MRF’ at an
O.D600nm of 0.5. To generate single clones infected E. coli was
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plated on 2x YT-agar supplemented with 100mM glucose and
100µg/mL ampicillin and incubated overnight at 37◦C.
Panning in Solution
For negative-selection of the TcdB-fragment phage library, a
cavity of a Costar High Binding microtiter plate was coated with
1 µg of an irrelevant scFv-Fc in 100 µL PBS overnight at 4◦C,
then blocked with panningblock for 1 h at room temperature and
subsequently washed 3x with PBST using a microplate washer.
109 cfu TcdB-fragment-phage were diluted in 150 µL 2% (w/v)
BSA in PBST and incubated in the negative-selection well for
1 h at room temperature. Magnetic protein A coated SureBeads
(Bio-Rad) were washed according to manufacturer’s instructions.
Phage were transferred to a protein low binding (PLB) microtube
(Sarstedt) and co-incubated with 15 µL resuspended beads for
1 h on a programmable rotator-mixer (PRM) (PTR-30 Grant-
bio) to further remove sticky or unspecific phage. Beads were
separated in a magnetic rack and phage containing supernatant
was transferred to a fresh PLB microtube and co-incubated with
100 ng scFv-Fc diluted in 150 µL blocking buffer [2% (w/v) BSA
in PBST] for 2 h on a PRM. An excess of magnetic protein A
coated SureBeads (Bio-Rad) was added to precipitate the scFv-
Fc fragments together with the bound TcdB-fragment phage
(30min, PRM). Beads were separated in a magnetic rack and
the supernatant was discarded. Beads were washed 10x with
1mL PBST, then resuspended in 150 µL trypsin (10µg/mL)
and incubated at 37◦C for 30min to elute the phage. Infection
to obtain individual clones was performed as described before
(Panning on immobilized scFv-Fc).
Production of Monoclonal TcdB-Fragment Phage and
Screening ELISA
Each well of a 96 well polypropylene U-bottom plate was filled
with 150 µL 2x YT-media [1.6% (w/v) tryptone, 1% (w/v) yeast
extract, 0.05% (w/v) NaCl] supplemented with 100mM glucose
and 100µg/mL ampicillin and inoculated with single E. coli
colonies derived from the panning (see above) and incubated
(37◦C, 800 rpm, Labnet Vortemp 56) overnight. The plate was
sealed with a breathable film (STARLAB INTERNATIONAL).
For phage production 150 µL of fresh 2x YT-GA per well
were inoculated with 10 µL overnight culture and incubated
at 37◦C and 800 rpm until cells reached exponential growth
phase. Cells were infected with 20MOI (multiplicity of infection)
Hyperphage (M13K071 gIII) (Rondot et al., 2001; Soltes
et al., 2007) for 30min at 37◦C without shaking and 30min
at 37◦C at 800 rpm. After pelleting for 10min at 3,220×g
cells were resuspended in phage production media (2x YT-
media supplemented with 100µg/mL ampicillin and 50µg/mL
kanamycin). Phage were produced during overnight incubation
at 30◦C and 800 rpm. Cells were pelleted at 3,220×g for 10min
and phage containing supernatant was used for screening ELISA.
For screening ELISA, a Costar High Binding microtiter plate
were coated with 100 ng scFv-Fc, respectively, 100 ng of irrelevant
scFv-Fc as control in 100 µL PBS overnight at 4◦C. Wells were
saturated with MPBST for 1 h at room temperature The plates
were washed 3x with water containing 0.05% (v/v) Tween20
before adding the monoclonal phage containing production
supernatant (25 µL in 75 µL MPBST). After 1 h incubation at
room temperature and 3x washing, bound phage were detected
using HRP conjugated anti-M13 antibody (GE 27-9421-01,
1: 40,000) for 45min at room temperature followed by 3x
washing. The detection was performed using TMB substrate. The
colorimetric reaction was stopped by addition of 100 µL 0.5M
H2SO4 and measured with an ELISA reader (TECAN Sunrise,
450 nm, reference 620 nm).
Epitope Mapping by Peptide Array
For epitope mapping by peptide array, custom microarray
slides were generated by PEPperPRINT (Heidelberg). Each
slide contained three copies of the TcdB array [TcdB 15mer
peptides with 13 amino acids (aa) overlap (2 aa offset)]. To
prepare the microarray slides, the array areas were hydrated
for 15min with 500 µL PBST [PBS 0.05% (v/v) Tween20] at
room temperature and slight orbital shaking (200 rpm). To avoid
unspecific binding of the scFv-Fcs, the arrays were blocked with
blocking buffer (MB-070, Rockland, Limerick, USA) for 30min
(room temperature, 200 rpm agitation). After washing with PBST,
1µg/mL (or 100µg/mL) scFv-Fc diluted in assay buffer [PBS
0.05% (v/v) Tween20 with 10% (v/v) Rockland blocking buffer]
was incubated on the array area (overnight, 4◦C, 200 rpm). To
remove unbound scFv-Fc, the arrays were washed three times
with PBST. The scFv-Fc was detected using a DyLight 680
conjugated anti-human Fc antibody (Biomol), diluted 1:2,000 in
assay buffer (30min, room temperature, 200 rpm agitation). The
array was washed three times with PBST, dipped in 1mM Tris
HCl pH 7.4 and dried in a jet of air. Slides were scanned and
fluorescence signals were detected at 700 nm with an Odyssey
Scanner (LI-COR Biotechnology GmbH). Afterwards, the HA-
tag control peptides were stained, using anti-HA Peptide Ready
Tag Mouse IgG2b (BioXcell) in a 1:5,000 dilution in assay
buffer as a primary, and Anti-Mouse IgG (H+L) DyLight 680
conjugated (Cell Signaling Technology) 1:5,000 in assay buffer
as a secondary antibody. Incubation with both antibodies was
30min at RT and 200 rpm, followed by three times washing with
PBST. After staining was completed, arrays were dipped in 1mM
Tris HCl pH 7.4, dried in a jet of air and used for a second scan.
Analysis of the scans was performed using PepSlide Analyzer
software (SICASYS Software GmbH).
RESULTS
Antibody Generation
To generate antibodies against the various domains of C. difficile
Toxin B (TcdB) a phage display approach was used. Phage display
was performed using the two naïve human scFv-libraries HAL9
and HAL10 (Kügler et al., 2015). To gain a broader antibody
diversity and to cover a broader range of epitopes six pannings
were performed on either domains or fragments of TcdB or the
full length toxin (TcdBFL) and at room temperature or 37
◦C. For
two pannings, a negative preselection on the N-terminal fraction
of TcdB was performed to direct the selection pressure toward
antibodies that bind within the TLD, more exactly, between aa
1,128 and 1,852. An overview over the panning strategies and
the success of the pannings is given in Table 1. After three
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TABLE 1 | Panning strategies.
Panning TcdB Fragment ◦C Antigen for
negative selection
Clones
screened
Clones
analyzed
Unique Produced and
characterized as
Fc-Fusion
ViF087 TcdB1−1852 RT TcdB1−1128 94 19 11 10
ViF088 TcdB1−1852 RT no 94 13 3 3
ViF090 TcdB1−1852 37 TcdB1−1128 94 17 2 2
ViF091 TcdB1−1852 37 no 94 11 1 1
ViF137 TcdBCROPs RT no 94 24 12 8
SH1429 TcdBFL RT no 92 12 7 7
Σ human antibodies 562 96 36 31
Overview over panning strategies and panning outcome.
rounds of panning a total of 562 clones were screened for
production of TcdB specific scFv in an antigen ELISA (data
not shown). On basis of the signal intensity and the signal
to noise ratio in the screening ELISA, 96 scFv clones were
further analyzed. Sequencing with subsequent V-gene analysis
and CDR comparison using the VBASE2 tool (Mollova et al.,
2010), revealed the isolation of 36 unique scFvs (Table 2). Of the
36 antibodies 15 (41%) are IGHV1, 18 (50%) IGHV3, two (5.5%)
IGHV5 and one IGHV6. No IGHV2 or IGHV4 antibodies were
isolated. The majority (29) of the isolated antibodies contained a
lambda light chain (9x IGLV1, 10x IGLV2, 8x IGLV3, 2x IGLV6)
and only 7 antibodies (18.9%) a kappa light chain (2x IGKV1, 5x
IGKV3).
The scFv genes were cloned into the mammalian expression
vector pCSE2.6-hIgG-Fc, which enables antibody production
in HEK293-6E cells in an scFv-Fc format. After protein A
purification of the scFv-Fcs from the culture supernatant,
purity of the mAb preparations was controlled by SDS-
PAGE and Coomassie staining (data not shown). There
were no visible impurities or breakdown products. Of
the 36 mAbs, 31 were successfully produced and further
analyzed.
Validation of Antigen Binding and Domain
Mapping
The 31 scFv-Fcs were analyzed by titration ELISA on four
different TcdB variants (TcdBFL, TcdB1−1852, TcdBGTD and
TcdBCROPs) first, to verify that format change from scFv to the
bivalent scFv-Fc did not impair antigen recognition, second,
to analyse TcdBFL binding of antibodies that were generated
on TcdB fragments, third, to validate antibody TcdB fragment
specificity and fourth, to determine the binding domains or
regions of the respective mAbs (Figure 2 and Table 3).
In this ELISA setup, all mAbs bound to their respective
panning TcdB variant in a concentration dependent manner. The
antibodiesViF137_C3 (Figure 2H) and SH1429_B10 (Figure 2I)
showed only weak binding in ELISA.
Interestingly, almost no binding to TcdBFL was detected for
some mAbs [ViF087_G11, ViF087_H5 (Figure 2A), ViF088_C5,
ViF088_E10, and ViF137_C2 (Figure 2E)] despite of binding to
the panning antigen. For further seven antibodies [ViF087_A10,
ViF087_B1, ViF087_B10, ViF087_F1 (Figure 2A), ViF091_B10,
ViF137A9, and ViF137_C1 (Figure 2E)] the binding to
TcdBFL was notably reduced (≤50% signal intensity at highest
concentration) compared to the respective panning TcdB variant.
As expected, there was no binding to TcdB1−1852 or TcdBGTD
of mAbs that were generated by panning against TcdBCROPs
[mAbs ViF137 (Figures 2F,G)] and no binding to TcdBCROPs of
mAbs that were generated by panning against TcdB1−1852 [mAbs
ViF087, ViF088, ViF090, and ViF091_B10 (Figures 2D,H)],
proving domain specificity of the mAbs generated in this study.
Of the 31 mAbs tested in this assay, 14 bound to
TcdBCROPs, among them all antibodies derived from the panning
against TcdBCROPs [mAbs ViF137 (Figure 2H)], as well as the
majority of the antibodies derived from the panning against
TcdBFL [SH1429_B10, SH1429_C10, SH1429_D6, SH1429_G1,
SH1429_G6 (only very weak), and SH1429_H7 (Figure 2L)].
Four mAbs [ViF087_E1, ViF088_C5, ViF088_H10, and
ViF090_A6 (Figures 2C,G)] bound to TcdBGTD indicating an
epitope within the GTD domain of TcdB. The remaining
13 antibodies bound to immobilized TcdB1−1852, but not to
TcdBGTD. Therefore, it is likely that these antibodies bound to
epitopes between aa 543 and 1,852, but due to possible differences
in protein folding between the different TcdB variants, a lack of
TcdBGTD binding in this experiment is not sufficient to exclude
an epitope within this domain.
In vitro Neutralization
In a next step, the antibodies were tested for in vitro
neutralization of TcdB. Therefore, a cell based assay with Vero
cells (African green monkey kidney cells) was chosen. Upon
cellular uptake of TcdB and release of the GTD into the cytosol,
the GTD glucosylates small Rho GTPases which impairs several
cell signaling pathways and consequently leads to a breakdown of
the actin cytoskeleton. This effect induces morphological changes
like the formation of retraction fibers and finally cell rounding
(Just et al., 1995). Neutralization efficacy of an antibody was
analyzed by comparing the percentage of round cells in samples
of cells treated with TcdB to cells treated with TcdB which was
preincubated with an antibody.
To determine the optimal working concentration of
TcdBFL for this assay, a serial dilution of TcdB in culture
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TABLE 2 | Overview over gene families of generated antibodies.
# mAb name V VH D VH J VH V VL J VL
1 ViF087_A10 IGHV1-18*01 IGHD3-3*01 IGHJ4*02 IGLV1-44*01 IGLJ3*02
2 ViF087_B1 IGHV3-30*04 IGHD3-10*01inv IGHJ6*02 IGLV1-47*01 IGLJ3*02
3 ViF087_B10 IGHV1-46*03 not found IGHJ6*02 IGKV3-20*01 IGKJ4*01
4 ViF087_E1 IGHV1-69*01 IGHD2-2*01 IGHJ4*02 IGKV3-15*01 IGKJ1*01
5 ViF087_E7 IGHV1-18*01 IGHD1-26*01 IGHJ3*02 IGKV1-12*02 IGKJ4*01
6 ViF087_F1 IGHV3-33*01 IGHD4-17*01 IGHJ2*01 IGLV3-19*01 IGLJ3*01
7 ViF087_F3 IGHV1-3*01 IGHD5-12*01 IGHJ5*02 IGLV2-18*02 IGLJ3*02
8 ViF087_G10 IGHV1-69*01 IGHD3-22*01 IGHJ5*02 IGLV1-47*01 IGLJ3*02
9 ViF087_G11 IGHV3-30*01 IGHD4-17*01 IGHJ4*02 IGLV3-19*01 IGLJ3*01
10 ViF087_H5 IGHV1-46*03 IGHD4-17*01 IGHJ4*02 IGLV2-14*01 IGLJ3*02
11 ViF088_C5 IGHV3-13*01 IGHD3-16*01 IGHJ4*02 IGLV6-57*01 IGLJ3*01
12 ViF088_E10 IGHV3-30*18 IGHD6-13*01inv IGHJ6*03 IGLV3-19*01 IGLJ3*02
13 ViF088_H10 IGHV3-33*01 IGHD3-10*01 IGHJ3*02 IGLV1-51*01 IGLJ3*02
14 ViF090_A6 IGHV1-69*01 IGHD2-15*01 IGHJ4*02 IGLV6-57*01 IGLJ3*02
15 ViF090_G5 IGHV1-3*01 IGHD5-12*01 IGHJ5*02 IGLV2-14*01 IGLJ3*01
16 ViF091_B10 IGHV1-69*06 IGHD2-21*01 IGHJ5*02 IGLV1-44*01 IGLJ3*02
17 ViF137_A3 IGHV3-23*04 IGHD6-19*01 IGHJ3*02 IGKV3-20*01 IGKJ4*01
18 ViF137_A6 IGHV3-7*01 IGHD6-13*01 IGHJ4*02 IGLV3-21*02 IGLJ3*01
19 ViF137_A9 IGHV5-51*01 IGHD1-14*01 IGHJ3*02 IGLV2-8*01 IGLJ3*02
20 ViF137_C1 IGHV3-23*04 IGHD5-5*01 IGHJ6*02 IGLV2-8*01 IGLJ3*01
21 ViF137_C2 IGHV3-23*01 IGHD5-18*01 IGHJ4*02 IGLV1-47*01 IGLJ3*02
22 ViF137_C3 IGHV1-69*01 IGHD6-13*01 IGHJ5*02 IGLV2-8*01 IGLJ3*01
23 ViF137_E4 IGHV3-21*01 IGHD6-19*01 IGHJ6*02 IGLV2-11*01 IGLJ3*02
24 ViF137_E7 IGHV5-51*01 IGHD1-1*01 IGHJ3*02 IGLV2-14*01 IGLJ3*02
25 SH1429_B1 IGHV1-3*01 IGHD5-12*01 IGHJ5*02 IGLV2-14*04 IGLJ1*01
26 SH1429_B10 IGHV3 IGHD2-8*02inv IGHJ3*02 IGKV3-20*01 IGKJ2*01
27 SH1429_C10 IGHV3 IGHD2-15*01 IGHJ6*02 IGLV2-8*01 IGLJ3*02
28 SH1429_D6 IGHV6 IGHD2-2*03inv IGHJ3*02 IGLV3-19*01 IGLJ1*01
29 SH1429_G1 IGHV3 IGHD2-2*02inv IGHJ3*02 IGKV3-20*01 IGKJ4*01
30 SH1429_G6 IGHV1-18*01 IGHD3-3*01 IGHJ4*02 IGLV1-40*01 IGLJ3*02
31 SH1429_H7 IGHV3 IGHD6-19*01 IGHJ4*02 IGLV1-47*01 IGLJ3*01
32 ViF087_C12 IGHV3-48*03 IGHD3-3*01 IGHJ3*02 IGLV3-19*01 IGLJ3*02
33 ViF137_A1 IGHV1-2*02 IGHD4-17*01 IGHJ5*02 IGLV1-51*01 IGLJ3*01
34 ViF137_A5 IGHV3-30*04 IGHD5-12*01 IGHJ4*02 IGLV3-19*01 IGLJ3*01
35 ViF137_D1 IGHV1-2*02 IGHD6-13*01 IGHJ4*02 IGKV1-5*01 IGKJ1*01
36 ViF137_D4 IGHV3-23*04 IGHD4-23*01 IGHJ4*02 IGLV3-19*01 IGLJ3*01
Antibodies not further analyzed are marked in gray.
media was applied to Vero cells. After 5 h, pictures of
the cells were collected and the percentage of round
cells was determined by counting using ImageJ software.
Cell rounding correlated with TcdBFL concentration (see
Supplementary Figure 1). For following neutralization
experiments, a TcdBFL concentration of 0.1 pM (resulting
in around 80% cell rounding) was coincubated with 100 nM
mAb in cultivation media and subsequently transferred to the
Vero cells.
To determine neutralization efficacy, the percentage of round
cells was determined and normalized to the percentage of round
cells in the control wells (Vero cells w/o TcdBFL and Vero cells
with TcdBFL w/o mAb).
In a first screening for neutralization, all tested mAbs
reduced the percentage of round cells after TcdB treatment
to some extent, with significant neutralization (p > 0.0001)
seen for 12 of 31 mAbs (Figure 3A). Preincubation of TcdB
with either ViF087_B1, ViF087_E7, ViF090_G5, ViF137_E4 or
SH1429_H7 resulted in more than 50% neutralization. Best in
vitro neutralization of TcdB was achieved with ViF087_A10,
ViF087_F3, or SH1429_B1 (>75% reduction of cell rounding).
TcdBFL neutralization of ViF087_A10 and SH1429_B1 was
further verified using serial dilutions of these antibodies
(Figure 3B). ViF087_F3 was not included since it contains the
same heavy chain as SH1429_B1 which suggests a neutralization
via the same mechanism, and size exclusion chromatography
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FIGURE 2 | Antigen ELISA on TcdB variants. 31 mAbs were tested for binding on 100 ng of immobilized fragments of TcdB or full length TcdB. Bound scFv-Fcs were
detected using an HRP conjugated anti-human Fcγ antibody. (A,E,I) Titration on TcdBFL; (B,F,J) Titration on TcdB1−1852; (C,G,K) TcdBGTD was used as antigen;
(D,H,L) Titration on TcdBCROPs.
revealed partial aggregation of ViF087_F3 which was not
seen for SH1429_B1 (data not shown). The dilution series
confirmed the results of the neutralization screening. At the
starting concentration of 100 nM ViF087_A10 or SH1429_B1
nearly completely inhibited the cell rounding induced by
TcdBFL intoxication (Figure 3B). However, the dilution series
revealed that SH1429_B1 is roughly 10 times more potent than
ViF087_A10, since 0.1 nM SH1429_B1 was sufficient to reduce
cell rounding by∼50% whereas 1 nM of ViF087_A10 was needed
to achieve a comparable effect.
Next, a combination of ViF087_A10 and SH1429_B1 was
tested to neutralize TcdBFL in an in vitro assay, but neutralization
achieved with this combination was not stronger than for
SH1429_B1 alone (data not shown).
Unlike Bezlotoxumab, a human anti-TcdB antibody already
approved by the FDA for therapy of recurrent CDI (Navalkele
and Chopra, 2018), the two most potent neutralizing antibodies
generated in this study (ViF087_A10 and SH1429_B1) bind
to epitopes within TcdB1−1852 (Figures 2B,J). Bezlotoxumab
binds to two epitopes within the CROPs. There are two
distinct neutralization mechanism possible for Bezlotoxumab:
i) blocking of interaction with carbohydrate structures and
therefore inhibition of cell binding (Orth et al., 2014), ii)
inhibition of binding to CSPG4 (Gupta et al., 2017). However,
this antibody proves that neutralization via this repetitive domain
is feasible. Nevertheless, there are three cellular receptors for
TcdB described that bind to specific receptor binding sites
within the TLD, e.g., members of the frizzled family binding
to TcdB1285−1804 with low nanomolar affinity (LaFrance et al.,
2015; Yuan et al., 2015; Tao et al., 2016; Gupta et al., 2017; Chen
et al., 2018). Hence it might be possible that the anti-TcdBCROPs
antibodies generated in this study reduce CROPs mediated
binding of TcdB to the cell surface but that TcdB induced cell
rounding is not reduced because of the numerous compensation
mechanisms mediated by the additional cell surface receptors. In
this case a combination of the mAbs directed against TcdBCROPs
with mAbs that bind to the N-terminal domains could lead
to improved neutralization and synergistic effects. To test this
hypothesis, combinations of either ViF087_A10 or SH1429_B1
with a mAb directed against TcdBCROPs were tested in an in
vitro TcdB neutralization assay. Therefore, 0.1 pM of TcdB was
preincubated with 1 nM ViF087_A10 or 0.1 nM SH1429_B1
[the concentration needed for ∼50% TcdB neutralization as
determined by titration (Figure 3B)] and 100 nM of either of
the 14 anti-TcdBCROPs mAbs for 30min at room temperature
and then transferred to Vero cells. TcdB neutralization for
each antibody combination was compared to neutralization
achieved with ViF087_A10, or SH1429_B1 alone in the same
assay.
Forty-one percent neutralization was observed for 1 nM
ViF087_A10 in this assay. Addition of 100 nM of a second mAb
directed against TcdBCROPs improved neutralization. The best
neutralization of ViF087_A10 was achieved in combination with
ViF137_E4 (73%), SH1429_C10 (70%) and SH1429_H7 (66%)
(Figure 4A).
0.1 nM of mAb SH1429_B1 reduced cell rounding by 49%. As
for ViF087_A10, addition of 100 nM of an anti-TcdBCROPs mAb
increased neutralization and best neutralizing with SH1429_B1
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FIGURE 3 | In vitro neutralization of TcdB. TcdB (0.1 pM) and mAbs were coincubated in cultivation media and transferred to subconfluent Vero cells in 96 well plates.
Pictures of each well were taken when cell rounding in NK control wells (TcdB w/o antibody) was 70–80%. Number of round cells were normalized to NK control and
percentage of round cells after media exchange (w/o toxin or antibody) was set to 100% neutralization. (A) Initial screening for neutralization using all 31 mAbs in a
10,000-fold molar excess. Bars represent technical triplicates with SD as error bars. A one-way ANOVA test was performed for each antibody against the isotype
control TM43_E10 (Kügler et al., 2015) *p < 0.0001. (B) IC50 of ViF087_A10 and SH1429_B1 were estimated with serial antibody dilutions.
was achieved in combination with the same TcdBCROPs binders
as for ViF087_A10, namely ViF137_E4 (79%), SH1429_C10
(78.9%) or SH1429_H7 (83.6%) (Figure 4B). Remarkably,
the anti-TcdBCROPs mAbs leading to the highest increase
of neutralization with either ViF087_A10 or SH1429_B1 in
this assay were the same mAbs that already showed best
neutralization among TcdBCROPs binders in the initial screening
as single antibodies (ViF137_E4 53%, SH1429_C1048%,
SH1429_H7 56%). Therefore, the increase of neutralization in
this combinatory assay seems to be based on additive rather than
synergistic effects.
Epitope Mapping
To identify the epitopes of ViF087_A10 and SH1429_B1 that
elicit neutralization, and gain more information about the
binding sites of the other antibodies, epitope mapping was
performed. To generate reliable data and to increase the chance
of identifying the epitopes or at least to narrow down the
binding regions of a significant number of antibodies, two
different approaches were used. First, all antibodies were tested
on a peptide array consisting of 15mer peptides of TcdB. The
maximum resolution of this array was two amino acids due
to the 2 aa offset of two neighboring peptides on the array.
This approach was successful for about 40% of the antibodies
(Table 3). Two antibodies (ViF137_A9 and ViF137_E7) were
found to exclusively bind to three clusters of peptides within the
CROP domain (1858–1869, 2084–2095, 2216–2227, and 1858–
1867, 2084–2093, 2218–2225, respectively) (Figure 5D). These
clusters contain a common motif which probably resembles
the key amino acids necessary for antibody-antigen interaction
[KYYF† († = D or N) and ∗KYYF† (∗ = I, S or D, † = D or N),
respectively]. The two neutralizing antibodies ViF087_A10 and
SH1429_B1 both specifically bound to the five 15mer peptides
starting between aa 414 and 422. ViF087_A10 additionally also
bound to the peptides starting at aa position 402 and 404
(Supplementary Figure 2).
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FIGURE 4 | In vitro neutralization of TcdB with antibody combinations. TcdB
(0.1 pM) and either 1 nM of ViF087_A10 (A) or 0.1 nM SH1429_B1 (B) mAbs
were coincubated in cultivation media with 100 nM of CROPs
binding mAbs.
For other antibodies, the results of the peptide arrays were less
clear.
For mAb ViF087-B10, a region within the GTD, represented
by four neighboring peptides starting at aa positions 288, 290,
292, and 294 was highly overrepresented among the fifteen
peptides showing the highest signal in the peptide array.
Nevertheless, this antibody seemed to have a broader cross-
specificity as the remaining signals originated from different
regions of the toxin and did not have common features. MAb
ViF087-E1 strongly, but not exclusively, bound to a peptide that
spans aa 522–537.
Furthermore, antibodies that bind to epitopes within
the CROPs, namely ViF137_A3, ViF137_A6, ViF137_C3,
SH1429_C10, SH1429_D6, and SH1429_G1, reacted with
peptides derived from the CROPs, but they did not exclusively
bind to only one cluster of neighboring peptides, but showed a
higher degree of cross-specificity or tolerance of aa substitutions,
therefore epitope identification only by peptide array was not
feasible for these antibodies. As expected, especially for short
(i.e., linear) epitopes, the peptide array approach yielded good
results.
Thus, to confirm the epitopes found by peptide array
and to identify further epitopes or at least binding regions
of the remaining antibodies, a phage display approach was
used. Therefore, a tcdB-gene fragment phage display library
was generated and packaged with Hyperphage (M13K071gIII)
to improve the presentation of correct open reading frames
(Supplementary Table 1). This library was used for pannings
on immobilized mAbs and/or for panning in solution with
subsequent immunoprecipitation using protein A coupled
magnetic beads. E. coli clones, carrying tcdB-gene fragments
coding for the potential epitope region, were identified by
monoclonal phage ELISA on immobilized mAbs. For 17 out of
31 mAbs the screening ELISA resulted in the identification of
monoclonal phage presenting TcdB fragments that specifically
bound to the corresponding anti-TcdB-mAb but not to an
irrelevant control mAb (data not shown). The related gene
fragments were sequenced, translated into aa sequences and
aligned to the TcdB sequence. For each mAb, the stretch of amino
acids that was covered by all sequenced clones that carried correct
inserts in the pHORF3 vector, is referred to as the minimal
epitope region (MER) (Table 3).
For two antibodies from pannings against TcdB1−1852,
ViF088_H10, and ViF090_A6, an almost identical MER in the
N-terminal part of the GTD was identified, comprising of aa 24–
84 and 23–83, respectively. These aa make up three alpha helices
that belong to an alpha helical bundle at the toxins N-terminus
(Figure 5A).
In the screening ELISA for ViF087_B10 only one clone tested
showed specific binding to its mAbs. This clone carried a TcdB
fragment spanning aa 289–313 which is in line with the result
from the peptide array.
The MER of the two best neutralizing antibodies generated in
this study (ViF087_A10 and SH1429_B1) is also located in the
GTD and comprises aa 423–433. For ViF087_A10, the signal-
to- noise ratio of epitope presenting clones in screening ELISA
was comparably low, nevertheless the MER was in accordance
to the binding pattern on the peptide array for both antibodies.
As shown in Figure 5B, the MER is located directly next to the
Rho-GTPase binding groove of TcdB.
The MER of ViF087_E1 was located between aa 528 and 543,
which corresponds to the C-terminus of the GTD (Figure 5C)
The MER overlaps with the peptide (aa 522–537) found with
the peptide array. For ViF137_A9 and ViF137_E7 the MERs
identified by phage display were in accordance with the results
of the peptide array, albeit for ViF137_A9 only one and for
ViF137_E7 only two of the three clusters were confirmed
(Figure 5D).
TheMER of ViF137_C3 was located in the N-terminal portion
of the CROPs and spans aa 1860–1992. For SH1429_D6, theMER
spanned a stretch of 118 amino acids in the middle of the CROPs
(aa 2010–2118) and the MER of SH1429_G6 aa 2228–2291.
The seven remaining mAbs (ViF137_A3, ViF137_A6,
ViF137_E4, SH1429_B10, SH1429_C10, SH1429_G1, and
SH1429_H7) for which the phage display approach was
successful, all bind to the C-terminal part of TcdB, therefore the
MERs resemble the last 70–130 aa of the toxin’s C-terminus.
For ViF137_A3, ViF137_A6, ViF137_C3, (Figure 5E),
SH1429_C10, SH1429_D6, and SH1429_G1 a re-evaluation
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FIGURE 5 | Crystal structures of the glucosyltransferase of TcdB (A–C, PDB 2bvm), the N-terminal (D,E PDB 4np4) and C-terminal (F, PDB 4nc2) fraction of the
CROP domain with highlighted epitopes of mapped antibodies. Figures were created using PyMOL (De Lano, 2002) (F) overview over epitopes mapped to TcdB in
this study. Neutralizing epitopes are highlighted in red. Neutralizing epitopes published by others are designated in gray (Orth et al., 2014; Kroh et al., 2018).
of the results of the peptide array was done after
identification of the MERs by phage display. In all
cases peptide clusters were identified that interacted
with the respective antibodies and which were in
accordance to the MERs identified by phage display
(Table 3).
DISCUSSION
The toxins TcdA and TcdB are main virulence factors for CDI.
The anti-TcdB antibody Bezlotoxumab was approved in 2016 by
the FDA for prevention of CDI recurrence. The corresponding
antibody Actoxumab, directed against TcdA, did not show
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clinical efficacy in clinical phase 31. In the clinical phase three
study (MODIFY II) the CDI recurrence was reduced from 26
to 16% by Bezlotoxumab (Wilcox et al., 2017). Because of this
limited efficacy and the fact that currently three different TcdB
receptors and a potential carbohydrate structure (Greco et al.,
2006; LaFrance et al., 2015; Yuan et al., 2015; Tao et al., 2016;
Gupta et al., 2017) are described as interaction partners, new
studies to describe neutralizing and non-neutralizing epitopes
are necessary, for further development of antibody combinations
that potentially improve clinical outcome. For these reasons, we
generated a set of novel human monoclonal antibodies targeting
TcdB using phage display.
We performed a total of six antibody selections using different
fragments/ functional domains of TcdB, and different panning
strategies. The panning strategies differed in regards of the TcdB
fragments and temperature used. Since all six panning strategies
led to the identification of unique and specific antibodies,
enrichment of specific antibody phage directed against the
different TcdB variants was successful in all cases. Sequencing
revealed the isolation of a total of 36 unique human antibodies.
In accordance to previous studies, pooling of lambda and kappa
libraries led to an enhanced but not exclusive selection of lambda
antibodies (80%) and also the subfamily distribution of selected
antibodies represents the pattern that was described before
(Kügler et al., 2015).
For further validation and characterization, the antibody
candidates were converted into the IgG like bivalent scFv-Fc
format. Due to a fast cloning and better production rates, this
format is preferred over the full IgG format for the rapid
screening of a higher number of candidate antibodies (Bujak
et al., 2014; Rasetti-Escargueil et al., 2017).
Thirty-one antibodies were tested for antigen binding and
domain specificity in an antigen ELISA on four different TcdB
variants (TcdBFL, TcdB1−1852, TcdBCROPs, and TcdBGTD). By
antigen ELISA on the respective panning antigen, we validated
that the antibody antigen interaction was not impaired by the
format change from scFv to scFv-Fc and switch of the production
system, since all antibodies bound to their respective antigen,
albeit 2 out of 31 weaker.
Interestingly, for five antibodies almost no binding to TcdBFL
was detected and for further seven antibodies the binding to
TcdBFL was drastically reduced compared to the respective
panning antigen. All these antibodies were generated on
fragments of TcdB, therefore the epitopes or binding regions of
these antibodies might not be accessible in the tertiary structure
of the full length TcdB or not folded correctly in the fragments.
For TcdA a 3D model of the holotoxin on the basis of electron
micrographs reveals the domain organization of the toxin (Pruitt
et al., 2010). In this model the CROPs form a long tail that
lays back onto the N-terminal portion of the toxin. Electron
micrographs of TcdB suggest a similar domain organization in
this homologous toxin (Pruitt et al., 2010). Epitope regions that
are located at the interface between CROPs and the N-terminal
portion of the toxin may be less accessible in the full length toxin
1Merck NewsroomHome (2015). Available online at: https://www.mrknewsroom.
com/ (Accessed September 26, 2018).
due to steric hindrance, which could explain reduced antibody
binding on full length TcdB. Different antibody binding on TcdB
fragments and full length TcdB was also shown by Chung and
coworkers (this issue of Frontiers Microbiology).
Fourteen of the antibodies characterized in this study bind
to TcdBCROPs, 14 to TcdB1−1852 but not to TcdBGTD. Despite of
depletion of the library by incubation on immobilized TcdB1−1128
prior to the panning in cases of panning ViF087 and ViF090,
four antibodies were obtained that bind to TcdB1−1852 and
TcdBGTD. For the domain mapping ELISA, an enzymatically
inactive GTD mutant (D286/288N) was used. Even though there
are only two amino acids exchanged, the overall structure of
the domain might be changed. Therefore, epitopes might not be
accessible or conformational epitopes might be destroyed. Loss
of antibody binding after mutation of single amino acids had
already been described in the literature for antibodies targeting
the diphtheria DT toxin (Bigio et al., 1987), among many
others. To avoid the generation of antibodies which are not
binding the full length protein, antibody generation strategies
could be applied with alternating panning rounds on full length
protein and protein fragments to focus on a particular epitope
(Thie et al., 2011).
Since CROPs, GTD, and TLD of TcdB all harbor epitopes
that can be targeted for neutralization (Babcock et al., 2006;
Marozsan et al., 2012; Wang et al., 2012; Maynard-Smith et al.,
2014; Anosova et al., 2015) all antibodies were subsequently
tested in an in vitro TcdB neutralization assay which is based on
cell rounding of Vero cells. All 31 mAbs reduced the percentage
of round cells after TcdB treatment to some extent and therefore
had slight neutralizing effects. However, of the 14 antibodies
directed against the CROPs domain only two (ViF137_E7 and
SH1429_H7) had neutralization efficacies of more than 75%. A
previous study showed, that generation of neutralizing antibodies
against TcdB CROPs is difficult through immunization as well
(Maynard-Smith et al., 2014). Based on homology to TcdA, the
CROPs of TcdB were proposed to harbor 4 putative carbohydrate
binding sites (Greco et al., 2006; Orth et al., 2014) which
may contribute avidity effects upon cell binding. These binding
sites share structural similarity (repetitive elements) but differ
in respect to their amino acid sequence, therefore it may be
difficult to develop a single antibody that completely blocks all
interactions between the CROPs and the carbohydrate structures.
As revealed by crystal structure analysis, the already approved
therapeutic antibody Bezlotoxumab binds to two epitopes within
the CROPs, therefore it was suggested that this antibody blocks
interaction of the CROPs with carbohydrate structures on the
cell surface (Orth et al., 2014). Nevertheless, binding to aa 1878–
1961 also inhibits interaction with CSPG4 receptor (Gupta et al.,
2017) and due to the existence of two epitopes within the
CROP domain also aggregation of the toxin as neutralization
mechanism cannot be excluded. As of today, it is not clear which
of the above mentioned is the major neutralization mechanism of
Bezlotoxumab.
The anti-CROPs mAbs generated in this study did not lead
to a substantially increased neutralization when applied together
with mAbs directed against the N-terminal fraction of TcdB (aa
1–1852), showing at most an additive effect.
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The two best neutralizers ViF087_A10 and SH1429_B1 with
neutralizing IC50 values of ∼1 nM and ∼0.1 nM, respectively,
are directed against the N-terminal fraction of TcdB (aa 1–
1852). Via antigen ELISA it was not possible to narrow down
the binding region to a single domain. Therefore, an epitope
mapping via peptide array and phage display was performed.
In these assays all antibodies were included with the hope
to identify correlations between epitopes and neutralization
efficacy. Unfortunately, but not unexpectedly, epitope mapping
by peptide array was not successful for the majority of the
tested antibodies. Since a prerequisite for binding of antibodies
to peptides immobilized on the array surface is that the
antibodies bind to continuous epitopes not including complex
folding (Abbott et al., 2014), this result suggests that most
of the identified human antibodies are very likely to bind to
complex conformational and/or discontinuous epitopes. This
hypothesis was also supported by data from immunoblot assays,
where most antibodies did not bind to denatured, linearized
TcdB (example given in Supplementary Figure 3). Nevertheless,
even though ViF087_A10 does not bind to denatured TcdB
in immunoblot and SH1429_B1 only very weakly, the core
of their epitope is a continuous aa stretch within the GTD
(aa 423–433 and 423–432, respectively). This epitope, primarily
found by peptide array, was also confirmed by antigen fragment
phage display, a method that also allows the identification of
conformational epitopes (Cariccio et al., 2016). Remarkably, both
neutralizing antibodies share the same epitope that is a surface
exposed α-helical secondary structure located in close proximity
to the substrate binding groove for the small Rho-GTPases
(Figure 5B).
This epitope is well conserved between the clinically most
relevant strains of CDiff clade 1 and clade 2 (hypervirulent
strains), however strains of the TcdA− TcdB+ in clade 4 show
some variance in this region.
Due to the localization of the epitope, at least two
neutralization mechanisms are possible for ViF087_A10 and
SH1429_B1: (i) inhibition of substrate binding or (ii) sterical
hindrance of TcdBGTD translocation through the pore. The
latter mode of action was recently described for the humanized
monoclonal antibody PA41 that binds to aa 290–360 (Kroh et al.,
2018).
For one antibody, ViF137_C3, an epitope (aa 1860–1992)
was found that includes one of the epitopes described for
Bezlotoxumab where aa 1902–1907 were shown to be partially
protected from H/D exchange by bezlotoxumab (Orth et al.,
2014). Nevertheless, TcdB neutralization achieved with this
antibody in cell rounding assays was only <50%. Unfortunately,
the minimal epitope region identified by phage display was larger,
thus not allowing conclusions on whether our antibody interacts
with the same amino acids of TcdB.
For most antibodies that exclusively bind to TcdB1−1852 and
TcdBFL in antigen ELISA it was not possible to determine the
epitope by neither of the methods tested. These mAbs probably
bind to complex discontinuous epitopes, including aa that are
located far apart on the primary structure of TcdB and only
come into close proximity upon folding of the polypeptide
chain. Such epitopes might be hard to display on phage due
to a selection pressure toward smaller peptides during library
packaging (Kügler et al., 2008) and potential misfolding of the
antigen fragments.
In conclusion, a panel of novel fully human monoclonal
antibodies was generated that target TcdB of C. difficile
(Figure 5F). A new neutralizing epitope was found located
within the GTD of TcdB. For future development of neutralizing
antibodies, the following regions may be addressed (i) aa 290–
360 (Kroh et al., 2018), (ii) aa 423 432 (epitope of the two best
neutralizers generated in this study), (iii) aa 1372-1493, involved
in binding to poliovirus receptor- like protein-3 (LaFrance et al.,
2015; Manse and Baldwin, 2015), (iv) aa 1810–1850, involved in
CSPG4 binding (Gupta et al., 2017) and aa 1430–1600 containing
the binding site for FZD- cysteine rich domain (Chen et al., 2018),
whereas the following regions may be omitted: (i) N-terminus
and C-terminus of GTD, since antibodies against these regions
generated in this study did not show significant neutralization,
(ii) the C-terminus of CROPs (Maynard-Smith et al., 2014; Gupta
et al., 2017).
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